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Systemic autoimmune diseases, such as 
systemic  lupus  erythematosus  (SLE), 
systemic  sclerosis,  and  Sjogren’s  syn-
drome (SS), are commonly character-
ized by circulating immunoglobulin G 
autoantibodies that include those spe-
cific for nuclear antigens (Sawalha and 
Harley, 2004; Routsias and Tzioufas, 
2007; Koenig et al., 2008). It is gener-
ally accepted that these antibodies trig-
ger  pathogenic  responses  by  forming 
immune  complexes  with  ubiquitous 
antigens  and  consequently  activating 
effector  responses  such  as  proinflam-
matory  cytokine  production.  Indeed, 
the severity of these systemic rheumatic 
diseases correlates with high levels of 
inflammatory  cytokines,  particularly 
type I IFNs and IL-12/23p40 (Baechler 
et al., 2004; Crow, 2007; Wong et al., 
2008).
Given  that  the  presence  of  auto-
antibodies is often the first sign of auto-
immune disease, and that these antibody 
responses persist, lymphocyte autoreac-
tivity is commonly viewed as the initiat-
ing event leading to chronic inflammatory 
conditions. In a strictly linear model,   
B cell autoreactivity against nuclear   
antigens is triggered by the synergistic 
activation of the B cell receptor and 
nucleic  acid–binding  TLRs.  In  this 
model,  the  subsequent  inflammatory 
condition is a direct consequence of self-
reactive antibodies produced by these 
activated B cells (Marshak-Rothstein, 
2006). Yet, additional factors can com-
plicate this simple linear model. B cell 
autoreactivity can be further augmented 
by the components of inflammation   
itself. For instance, IFN- up-regulates 
TLR expression (Thibault et al., 2008), 
and, as a result, B cells remain sensitive 
to inflammatory signals and are more 
responsive to the adjuvant effect of 
TLR-binding nucleic acids. Addition-
ally,  inflammatory  cytokines  bolster 
multiple arms of the immune response, 
which helps sustain the proinflamma-
tory state. For example, type I IFN can 
extend the activated T cell response, 
enhance humoral immunity, and pro-
mote antigen presentation (Blanco et al., 
2001; Le Bon et al., 2001; Marrack   
et al., 1999). If unchecked, these nor-
mally beneficial responses can be path-
ological.  Thus,  systemic  autoimmune 
disease could result from continuous 
inflammatory signals that create a feed-
back amplification loop of autoreactive 
pathological responses, resulting in sys-
temic disease (Fig. 1). On p. 1661 of 
this issue, Espinosa et al. (2009) de-
scribe an animal model in which local 
injury–elicited  inflammation  initiates 
systemic  autoreactivity,  providing  an 
example of the reciprocal nature of au-
toreactivity and inflammation.
Cytokines in inflammation  
and autoimmunity
Both gene expression profiling and ge-
netic studies have revealed an association 
between the type I IFN pathway and 
susceptibility to the autoimmune disease 
SLE.  Microarray  analysis  of  PBMCs 
from  lupus  patients  demonstrated  in-
creased expression of a common set of 
IFN-inducible genes (Ly6E, Oasl, Ifit1, 
Stat1, Mx1, Mx2, Plscr1, and Irf7), which 
are  called  the  “lupus  IFN  signature” 
(Baechler  et  al.,  2003,  2004;  Bennett   
et al., 2003). The IFN gene signature 
also appears to reflect an IFN protein 
signature,  as  severity  of  disease  was 
shown to correlate with increased levels 
of type I IFN-inducible chemokines in 
the serum (Crow, 2007). The link be-
tween IFN pathways and autoimmune 
disease is reinforced by the strong ge-
netic linkage between genes regulating 
the IFN signature and disease, the most 
prominent being Irf5 and Tyk2 (Shaw   
et al., 2003; Sigurdsson et al., 2005;   
Kozyrev and Alarcon-Riquelme, 2007). 
IRF-5  is  required  for  TLR-mediated 
activation  of  inflammatory  cytokines 
and type I IFN, and TYK2 is a tyrosine 
kinase associated with type I IFN signal-
ing. The current view is that enhanced 
activity of either IRF5 or TYK2 accel-
erates type I IFN production and/or 
signaling  and  exacerbates  autoreactive 
inflammatory pathology. The resultant 
high levels of type I IFN and of type I 
IFN-inducible genes in SLE patients 
may contribute to a vicious positive 
feedback loop that leads to chronic in-
flammation and autoimmunity. Other 
cytokines induced by IRFs, including   
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reported by Espinosa et al. (2009) in this 
issue connects Ro52 to an IFN-associ-
ated negative feedback loop that pre-
vents unrestrained inflammation.
Ro/SS-A antigens: targets or culprits?
Autoantibodies to the Ro antigen (also 
called  SS-A,  for  SS  type  A  antigen), 
which are associated with UV hypersen-
sitivity, are frequently detected serologi-
cal autoimmune markers in rheumatoid 
diseases (Schulte-Pelkum et al., 2009). 
Anti-Ro sera may be directed against two 
different  polypeptides  with  seemingly 
unrelated  functions:  Ro52  and  Ro60. 
Ro52,  an  E3  ligase  that  ubiquitinates 
various members of the IRF family, is 
an IFN-inducible protein of the TRIM 
family that translocates to the nucleus 
upon IFN- stimulation (Rhodes et al., 
2002; Strandberg et al., 2008). Although 
its role in regulating the IFN pathway 
has been controversial, there is evidence 
that Ro52 can both promote and abrogate   
inflammation. Ubiquitination of IRF8 by 
Ro52 amplifies IL12p40 production and 
plays an essential role in promoting IFN 
I production during antiviral responses 
(Kong et al., 2007). On the other hand, 
Ro52 negatively regulates type I IFN by 
ubiquitin-mediated degradation of IRF3 
(Higgs et al., 2008).
Ro60  is  part  of  the  Ro/La  ribo-
nucleoprotein (RNP) complex that asso-
ciates  with  a  small  cytoplasmic  RNA 
(RNA-Y) of unknown function. Analy-
sis of its crystal structure suggests that 
Ro60  binds  and  stabilizes  misfolded 
RNA (Stein et al., 2005). Mice deficient 
in Ro60 develop a lupus-like syndrome, 
although with a substantial genetic com-
ponent (Xue et al., 2003). It has been 
hypothesized  that  misfolded  RNA 
might  accumulate  in  the  absence  of 
Ro60 and cause a breach of tolerance by 
exposing normally cryptic determinants 
to the immune system. It was also sug-
gested that UV damage might induce 
the accumulation of misfolded RNA in 
the absence of Ro60, provoking an in-
flammatory response. Ro60’s protective 
role  in  eliminating  autoimmunity-
  inducing  nucleic  acids  might  parallel   
the preventive function suggested for 
the cytoplasmic nucleases TREX1 and   
RNaseH2,  which  are  both  strongly 
accelerates disease (Mathian et al., 2005). 
In addition, elevated levels of IL-17 and 
IL-23 have been found in lupus patients 
(Crispín et al., 2008; Doreau et al., 2009) 
and in animal models. However, defini-
tive proof of the involvement of these 
cytokines  in  lupus  pathology  remains 
elusive, as genetic deletions of these cy-
tokines in mice have generated conflict-
ing results (Garrett-Sinha et al., 2008).
Although  type  I  IFN  is  primarily   
associated with the induction of in-
flammatory cytokines, it also induces 
regulators that counteract inflammation. 
Among the IFN-inducible factors that 
provide negative feedback regulation in 
inflammation are some members of the 
tripartite motif (TRIM) family of pro-
teins, which are important components 
of antiviral defense (Ozato et al., 2008). 
TRIM21, also called Ro52, is frequently 
a target autoantigen in rheumatic dis-
eases (Schulte-Pelkum et al., 2009). The 
characterization of Ro52-deficient mice 
IL-6, TNF, IL-12/IL-23p40, and ulti-
mately IL-17 (Tailor et al., 2006), can 
subsequently  amplify  autoreactivity  by 
way of T cell activation, germinal center 
expansion, B cell survival, neutrophil in-
filtration, and TLR up-regulation (Le Bon 
et al., 2001; Hsu et al., 2008; Thibault   
et al., 2008; Doreau et al., 2009).
The relevance of the type I IFN and 
IL-17 pathways in the development of 
systemic autoimmune disease has been 
revealed in several studies. In humans, 
IFN-–treated subjects often test posi-
tive for antinuclear antibodies, although 
few  develop  autoimmune  pathology 
(Kälkner  et  al.,  1998).  Mutations  in 
genes encoding the antiviral nucleases 
TREX1 and RNaseH2 are associated 
with an increased production of IFN- 
and  are  linked  to  both  the  Aicardi-
Goutieres  syndrome  and  early-onset 
SLE  (Crow  et  al.,  2006;  Rice  et  al., 
2007,  2009;  Stetson  et  al.,  2008).  In   
lupus-prone  mice,  injecting  IFN-  
Figure 1.  Amplification loop of inflammation and autoreactivity. Injury-induced inflamma-
tory pathways, including IL-23/Il-17 and type I IFN, can amplify autoreactive conditions by increas-
ing the likelihood of B cell–T cell interaction and by promoting the presentation of self-antigens. 
Autoantibodies that have been produced in these conditions further propagate the inflammatory 
pathology by forming immune complexes that activate effector cells. IRFs are essential for the  
IL-23–IFN pathway, and their activity can be down-regulated by IFN-inducible factors such as the 
Ro52 ubiquitin ligase. Ro52 and other IFN-inducible factors commonly provide novel epitopes for  
autoreactivity.JEM VOL. 206, August 3, 2009 1649
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disease. Cross-reactive antibodies toward 
epitopes within Ro52 and Ro60 could 
develop during the response, T cells could 
provide help to B cells presenting self-
epitopes derived from macromolecular 
complexes, or immune complexes taken 
up through Fc receptors could be subse-
quently presented by an activated APC 
(Fig. 1). Any of these mechanisms could 
account for the fact that peripheral T cell 
tolerance  against  these  Ro  and  RNP   
antigens seems to be particularly fragile 
both in human and mice.
TRIM factors and innate immunity
The TRIM superfamily includes >60 
members whose functions are generally 
linked to the regulation of innate re-
sponses and viral defense (Ozato et al., 
2008). The tripartite motif present in 
TRIM  molecules  comprises  a  RING 
domain, B-box domain, and a coiled–
coil domain. RING domains mediate 
the conjugation of proteins with ubiq-
uitin or other ubiquitin-like molecules, 
and coiled–coil domains promote self-
aggregation.  Similar  to  Ro52,  many 
TRIM proteins are IFN-inducible E3 
ubiquitin ligases. Interestingly, TRIM 
proteins can participate in viral innate 
immunity in different ways. Some have 
direct antiviral functions. For instance, 
TRIM5 interferes with HIV viral pre-
integration complex uncoating (Sayah 
et al., 2004; Stremlau et al., 2004), and 
TRIM19, or PML, inhibits the growth 
of numerous RNA and DNA viruses 
(Chelbi-Alix et al., 1998). Other TRIM 
proteins modulate antiviral responses by 
regulating IRF and NF-B pathways. 
TRIM25’s  ability  to  ubiquitinate  and 
subsequently  activate  the  CARD  do-
main in RIG-I activates NF-B and in-
duces  IFN  production.  (Gack  et  al., 
2007)  The  degradation  of  TAB2  and 
TAB3 by TRIM30, on the other hand, 
inhibits TRAF6 and inactivates NF-kB 
(Shi et al., 2008). The discovery by   
Espinosa et al. (2009) that Ro52 defi-
ciency leads to autoimmunity expands 
our knowledge on the delicate balance 
orchestrated by TRIM factors to mod-
ulate immune responses and highlights 
its important regulatory function. Thus, 
although a robust induction of antiviral 
inflammatory responses is beneficial to 
acid-triggered inflammation by inhibit-
ing  the  DNA  sensor  AIM2  (Roberts   
et al., 2009; Rozzo et al., 2001). TRIM68, 
also called SS-56, is another IFN-induc-
ible autoantigen found in patients with 
SLE and Sjogren’s disease that is struc-
turally  similar  to  Ro52  (Rice  et  al., 
2009). Thus, TRIM antigens and Ifi202 
not only control IFN responses and be-
have  as  autoimmune  suppressors,  but 
they are also common targets of autore-
activity. The regulatory role of Ro52 in 
inflammation provides a possible expla-
nation for the correlation between ge-
netic  polymorphisms  in  Ro52  with 
disease and increased anti-Ro antibodies 
(Nakken et al., 2001).
It is possible that autoreactivity against 
IFN-inducible proteins could be a con-
sequence of enhanced antigen presen-
tation capacity of IFN-activated APCs. 
In fact, a major effect of type I IFN is   
to enhance dendritic cell maturation 
(Blanco et al., 2001; Le Bon et al., 2001; 
Longhi et al., 2009). Intriguingly, be-
cause some of these factors translocate 
to the nucleus and interact with RNA 
upon IFN activation, their antigenicity 
could be the result of RNA-mediated 
TLR activation combined with novel 
epitope presentation. RNP complexes 
contain  RNA-Ys,  which  have  been 
shown to promote dendritic cell matu-
ration and IFN production (Kelly et al., 
2006). These effects are dependent on the 
TLR adaptor protein MyD88 and endo-
some acidification, pointing to an endog-
enous adjuvant effect through TLR7 
activation. The potential association of 
Ro52 with RNA-binding molecules in 
IFN-induced supramolecular complexes 
could promote the presentation of Ro52 
epitopes upon translocation to the nu-
cleus or other cellular compartments.
Although the association of Ro52 
with Ro60 and RNPs has not been con-
clusively demonstrated, antibodies against 
Ro52 and Ro60 arise concurrently in 
SLE patients and epitope spreading be-
tween Ro52 and members of the RNP 
complex has been repeatedly observed 
after  immunization  in  animal  models 
(Deshmukh et al., 2005). It is still unclear 
how  the  epitope  spreading  occurs,   
although  various  pathways  have  been 
invoked that may act at various stages of 
linked  to  autoimmune  susceptibility 
(Crow et al., 2006; Rice et al., 2007, 
2009; Stetson et al., 2008). Alternatively, 
Ro60 deficiency could result in immune 
dysregulation of the type now reported 
for Ro52-deficient mice.
Espinosa  et  al.  (2009)  show  that 
Ro52-deficient  mice  develop  uncon-
trolled inflammation and systemic auto-
immunity as a consequence of minor 
tissue injury caused by ear tagging. The 
general  autoimmune  pathology  and 
neutrophil recruitment to the site of in-
jury were completely IL-23 dependent, 
as they were not observed when mice 
lacking Ro52 were crossed to IL-23p19–
deficient animals. Characterization of im-
mune cells derived from Ro52-deficient 
mice demonstrated that in addition to 
ubiquitinating the previously reported 
targets  IRF3  and  IRF8,  Ro52  was   
required  for  polyubiquitination  and 
degradation of IRF5.
The authors also report that Ro52-
deficient bone marrow–derived macro-
phages  and  splenocytes  released  more 
inflammatory cytokines (IL-6, TNF, type 
I IFN, and IL-23) upon TLR activation. 
Overall, these data demonstrate that the 
ubiquitin ligase Ro52 is induced by IFN 
activation of immune cells, where it acts 
as a negative regulator of IFN signaling. A 
recent study by Yoshimi et al. supports 
these  conclusions  and  also  shows  that 
Ro52 is a negative regulator of IFN I in 
vivo (Yoshimi et al., 2009).
The phenotype of Ro52-deficient 
mice thus provides a mechanistic view 
of how environmental factors could ini-
tiate autoimmune disease. For example, 
localized  tissue  injury  from  UV  light 
damage  or  infection  could  provoke 
unrestricted IL-23/IL-17–mediated in-
flammation and subsequent autoimmu-
nity in susceptible individuals.
Interestingly, the fact that Ro52 itself 
is a common autoantigen in rheumatic 
diseases  and  that  other  IFN-inducible 
proteins,  including  Ifi202,  Ifi16,  and 
Hsp70, have been identified as autoanti-
gens in murine and human disease, re-
veals that IFN-inducible genes are often 
the  targets  of  self-reactivity  (Hueber   
et al., 2004; Zhuang et al., 2005). The 
autoantigen Ifi202 is both a lupus sus-
ceptibility gene and a regulator of nucleic 1650 Ro52 LINKS AUTOIMMUNITY AND INFLAMMATION | Bolland and Garcia-Sastre
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Final thoughts
Systemic autoimmune diseases resemble 
responses to chronic viral infections that 
consequently result in an unrestrained, 
autoreactive  amplification  loop.  It  is 
possible that the main factor determin-
ing whether normally healthy immune 
responses turn into chronic autoimmune 
disease  is  not  the  intensity  of  the  re-
sponse or the incidence of autoreactivity 
at a given moment, but instead the abil-
ity to abort a self-propagating loop of 
inflammation  and  autoreactivity.  This 
requires  an  exquisite  balance  between 
initiating  effective  immune  responses 
and  promptly  terminating  them  once 
they are no longer beneficial, potentially 
explaining why genes involved in the 
regulation  of  inflammatory  pathways, 
such as Ro52 and IRFs, are often found 
to be genetically associated with autoim-
mune disease. Modest alterations in gene 
dose  or  expression  could  disrupt  this 
delicate balance and perpetuate a patho-
logical  feedback  loop.  Thus,  targeting 
Ro52 activity may be useful for treating 
autoimmunity  or  even  for  enhancing 
antiviral vaccine responses.
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